Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
116 hedge funds and large institutions have $589M invested in Accelerate Diagnostics in 2018 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 33 reducing their positions, and 15 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 33
1% less funds holding
Funds holding: 117 → 116 (-1)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
11% less capital invested
Capital invested by funds: $665M → $589M (-$75.6M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
55% less call options, than puts
Call options by funds: $6.54M | Put options by funds: $14.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$45.6M |
| 2 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$5.86M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$5.28M |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$4.92M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$10.2M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.97M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$7.7M |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$7.44M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.22M |
AXDX Hedge Fund Activity: Q1 2018 in Review
116 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q1 2018, worth a combined $589M — down 11% from $665M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AXDX and 14 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 34 added.
The largest buyer was Credit Suisse, adding an estimated $45.6M. The largest seller was William Blair & Company, cutting an estimated $10.2M.
- 116 institutional investors held Accelerate Diagnostics (AXDX) as of Q1 2018, down from 117 in Q4 2017.
- Funds reported $589M of Accelerate Diagnostics stock for Q1 2018, down 11% quarter-over-quarter.
- 14 funds opened new Accelerate Diagnostics positions in Q1 2018 and 15 closed out, a net change of -1 holder.
- The largest Accelerate Diagnostics buyer in Q1 2018 was Credit Suisse, an estimated $45.6M added.
- The largest Accelerate Diagnostics seller in Q1 2018 was William Blair & Company, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2018.